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Introduction
The term “breakthrough reactions” refers to repeated hypersen-
sitivity reactions to iodinated contrast media (ICM), nowadays 
non-ionic, low-osmolality contrast media, despite premedication 
with glucocorticoids and antihistamines (1-4). A large amount 
of literature has been formerly written on this topic, when im-
munological mechanisms beyond hypersensitivity reactions were 
quite neglected (1-6). In fact, breakthrough reactions were often 
described without distinguishing if occurring after injection of 
the same rather than a different ICM responsible of the prior re-
action (1,3,4). From a clinical perspective, patients with break-
through hypersensitivity reactions to ICM are often patients who 
undergo and require many contrast-enhanced examinations, such 
as patients with oncologic or cardiovascular diseases. Thus, the 
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Summary
Background. The term “breakthrough reactions” designates repeated hypersensitivity reac-
tions to iodinated contrast media (ICM) despite premedication with glucocorticoids and an-
tihistamines. We aimed to retrospectively evaluate the rate of positive skin test (STs) in our co-
hort of patients with previous breakthrough reactions to different ICMs. Methods. A series of 
35 patients, who experienced at least one breakthrough reaction to ICM and who underwent 
STs within 6 months from the reaction were studied, and results were compared to a control 
group of patients with a first hypersensitivity reaction occurred without premedication. Skin 
prick tests (SPT), intradermal tests (IDT) and patch tests (PT) at different dilutions, with a 
set of three to four ICM were performed. Results. Of the 35 patients with prior breakthrough 
reactions, 57% had an immediate reaction (IR) and 43% had a non-immediate reaction 
(NIR). Patients who experienced the first hypersensitivity IR or NIR, later had one or more 
breakthrough IR or NIR, respectively. Overall, 29% (10/35) of patients with prior break-
through reactions resulted positive to STs compared to 57% (16/28) of the control group (p < 
0.05). No significant difference in allergy history, age, sex, other clinical / demographic fea-
tures nor chronic use of ACE-inhibitor, beta-blockers or NSAIDs was observed. Conclusions. 
This preliminary finding suggests that patients with prior breakthrough reactions have signifi-
cantly lower immunologically proven ICM reactions (positive STs) if compared to non-break-
through patients. According to that, a considerable number of breakthrough reactions seems 
to be non-allergic hypersensitivity reactions or reactions which could be mostly prevented by a 
proper, well-timed skin testing. Larger prospective studies are needed to confirm these results, 
with a more careful analysis of patients’ risk factors, a laboratory assessment that includes an 
in vitro allergy diagnostics, and hopefully a drug provocation test for selected cases.
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not included. Similarly, STs were performed between 2 and 6 
months from the hypersensitivity reaction in the control group.
Iomeprol (Iomeron 350 mg/mL), iopromide (Ultravist 370 
mg/mL) and iodixanol (Visipaque 320 mg/mL) were chosen 
for STs, being the only ones used in our center for radiologi-
cal examinations in the last 8 years (CT-scan, conventional an-
giography, cholangiography and urography) (11). Hence, if a 
patient experienced a hypersensitivity reaction to ICM in our 
Radiology Department in this time interval, the culprit should 
be searched among one of this three. For those patients who 
experienced the index reaction elsewhere, we added the culprit 
compound, if different from these three, to the aforementioned 
panel used for STs. 
SPT were performed with undiluted commercially available 
ICM solution, IDT was administered at gradually increasing 
concentrations of 1:100, 1:10 and then 1:1 dilutions, where-
as PTs were performed with undiluted ICM and all the results 
were interpreted according to the International Guidelines and 
the ENDA study protocol (10,13). SPT and IDT were evalu-
ated after 20 minutes (immediate reading), while PT and IDT 
were evaluated after 48, 72 and 96h (delayed reading). 
Reaction time and severity. As previously described by our group 
(11), Hypersensitivity reaction were divided according to the 
time between ICM injection and reaction onset. Immediate re-
actions (IRs) were defined as those developing within one hour 
after ICM injection, whereas non-immediate (or delayed-type) 
reactions (NIRs) as those developing from one hour to one week 
after contrast media administration (9). Immediate reactions 
were assessed according to the Ring and Messmer classification 
from grade 1 to 4 as follow: grade 1 for generalized cutaneous 
and/or mucocutaneous rash, skin eruption, urticarial, angioede-
ma and pruritus; grade 2 for mild systemic reactions including 
skin manifestations, abdominal symptoms (nausea, cramp-
ing), respiratory symptoms (rhinorrhea, hoarseness, dyspnea), 
cardiovascular symptoms (tachycardia Δ > 20 / min); grade 3 
for life-threatening systemic reactions including abdominal 
symptoms (vomiting, diarrhea), respiratory symptoms (laryn-
geal edema, bronchospasm, cyanosis), cardiovascular symptoms 
(hypotension > 20 mmHg sys., arrhythmia, shock); and grade 
4 for cardiac and/or respiratory arrest (16). Non-immediate re-
actions were defined as mild when no treatment was required, 
moderate when the patient responded quickly to an appropriate 
treatment (e.g. oral glucocorticoid), and severe when the reac-
tion was life-threatening, required hospitalization or resulted in 
death (9).
Premedication regimen. All the patients were premedicated with 
the same regimen of corticosteroids and antihistamine before 
undergoing the radiological procedure, as already described in 
other study-cohort (11). Briefly, the premedication regimen 
used in our center is approved and adopted by the American 
selection of a safe alternative compound is fundamental and starts 
from the demonstration of the patient’s sensitization to one or 
more ICM assessed by skin tests (STs) (7-10). 
The reliability of STs in diagnosis of ICM allergy has already 
been assessed in patients with prior hypersensitivity reaction to 
ICM (10-14). In particular, ENDA conducted a prospective 
multicenter study which demonstrated that a diagnosis could 
be reached in up to 50% of patients with prior hypersensitivity 
reactions to ICM if tested by STs (namely skin prick tests, in-
tradermal tests and patch tests) between 2 and 6 months after 
the reaction (10). 
Since true sensitivity of STs in patients with prior breakthrough 
reactions are still unknown, we retrospectively analyzed the 
rate of positive STs performed within 6 months after (the last) 
breakthrough reaction in these patients and compared this data 
to a control group that experienced a hypersensitivity reaction 
to ICM without premedication.
Material and methods
Patients. Data of patients who had one or more hypersensitivity 
reactions to ICM despite pharmacological premedication in our 
Radiology Department between December 2006 and December 
2014 were collected. Patient demographics; risk factors; ICM 
culprits; signs, symptoms, severity and timing of each index and 
breakthrough reaction were reported, as suggested by ENDA 
questionnaire for drug hypersensitivity (15). We also included 
patients who experienced breakthrough reactions in our Radiol-
ogy Department, but who experienced the first hypersensitivity 
reaction to ICM (the one occurred without premedication, also 
called index reaction) elsewhere, only if the ICM of the index 
reaction was known. A total of 35 patients was collected. 
We compared STs results with a control group of patients who 
had a hypersensitivity reaction to ICM without pharmacologi-
cal premedication in our Radiology Department between Jan-
uary and December 2014, which were tested with STs at the 
same conditions of the breakthrough patients’ group. Data of 
28 patients were collected.
Written informed consent was obtained for the procedure. No 
ethical committee approval was requested for this observational 
analysis, since all tests are already accepted as routine tools and 
were performed for diagnostic purposes.
Skin tests and contrast media. We included only those patients 
who were tested by skin prick test (SPT) and intradermal test 
(IDT) with a set of three ICM (iomeprol, iopromide, iodixa-
nol), between 2 and 6 months from the breakthrough reaction 
(or the last breakthrough reaction if more than one) (10,13). 
Patch test (PT) were performed only in patients with non-im-
mediate reactions (10). Given the retrospective nature of the 
study and its purpose, patients with STs performed after index 
reaction and before breakthrough reaction in study cohort were 
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reactions. In 34 out of 38 breakthrough reactions ICM culprit 
were known (89% of patients); while in the control group, ICM 
culprit was known in 100% of cases (table 1 for details). 
Hypersensitivity reactions’ severity. Among patients of the break-
through group, IRs were experienced in 20 and NIRs in 15. 
Of note, each index IR was followed by one or more IRs and 
each NIR was followed by one or more NIRs. Among index 
IRs, 45% were assessed as grade I, 20% as grade II, and 35% as 
grade III, whereas among index NIRs, 87% were graded as mild 
and 13% as moderate reactions. Among breakthrough IRs, 48% 
was grade I and 52% grade II and among breakthrough NIRs, 
only 73% were considered mild and 27% moderate reactions. 
In the control group, 53% of IRs were assessed as grade I, 29% 
as grade II and 18% as grade III. Almost three quarters of NIRs 
were considered mild, 27% moderate and none severe (table 1). 
Patients with prior breakthrough reactions have low rate of posi-
tive ST. All patients tested presented a histamine wheal ≥ 3 mm. 
Overall, 29% (10/35) of patients with prior breakthrough reac-
tions had positive STs to one or more ICM tested. Among these 
10 patients, 6 had a prior IR and 4 had a prior NIR. Details are 
reported in table 2 and table 3. In the control group, the rate 
of positive STs to one or more ICM tested was 57% (16/28). 
Among these 16 patients, 10 had a prior IR 6 had a prior NIR. 
The difference between breakthrough and control groups was 
statistically significant (P < 0.05). There was no difference in 
STs positive rate comparing each other IR subsets of break-
through and control group and NIR subsets of breakthrough 
and control group (p > 0.05 in both comparisons). 
In the cohort of patients with prior breakthrough reactions, 
none of the patients had positive SPT, whereas 9/10 patients 
had positive IDT (6 IR patients and 3 NIR patients) and one 
of the NIRs group had also positive PT only (table 2 and 3 for 
details). The median time interval between the first reaction and 
skin testing was 5 months (range 2 - 6). 
The culprit ICM of the breakthrough reaction (or the last 
breakthrough reaction if more than one) was known in 33 out 
of 35 patients, 19 with IRs and 14 with NIRs. The culprit ICM 
elicited a positive ST in 26% (5/19) of IR patients and in 21% 
(3/14) of NIR patients. As mentioned, all STs were performed 
within 6 months from the last breakthrough reaction. The cul-
prit ICM of index reaction (occurred from 6 months to 8 years 
before STs) of the breakthrough cohort, was known in 51% 
(18/35) of patients, 10 with IRs and 8 with NIRs. Three of 
them tested positive to the implicated ICM, 20% (2/10) of IR 
patients and 13% (1/8) of NIRs. In 2 of the 3 patients of IR 
group who experienced two breakthrough reactions each, the 
ICM used of both breakthrough reactions were the same and in 
one the ICM was unknown (table 2).
In the control group, none of the patients had positive SPT or 
PT, whereas 16/16 patients had positive IDT (10 IR patients 
College of Radiology (8): Methylprednisolone (Medrol®) 32 mg 
by mouth 12 hours and 2 hours before ICM administration 
and Hydroxyzine Hydrochloride (Atarax®) - 25 mg by mouth 1 
hour before ICM administration.
Statistical Analysis. Continuous variables are expressed as aver-
age (range minimum-maximum value), unless otherwise speci-
fied. Qualitative data were expressed in frequency and percent. 
Fisher’s exact test and Student’s T test were used for statistical 
comparison between groups. Differences with P-values below of 
0.05 were considered statistically significant.
Results
Patients’ features. We identified 58 patients with prior break-
through hypersensitivity reactions, but 23 did not fulfilled the 
study criteria (STs were performed after 6 months form the least 
breakthrough reaction). A total of 38 hypersensitivity reactions 
to ICM despite pharmacological premedication occurred in 35 
patients (mean age 58 years, range 26-78). The 57% (20/35) of 
patients had an index IR, whereas the 43% (15/35) of patients 
had an index NIR. All index IRs and NIRs were subsequently 
followed by one or more breakthrough IRs and NIRs respec-
tively (table 1). 
Sixteen patients (46%; 8 patients of the IR group and 8 of the 
NIR group) reported a history of previous hypersensitivity reac-
tions to agents different from ICM. In particular, drug hypersen-
sitivity was the majority of cases (75%), half of which were severe 
(50%). The 66% (13 patients with IR and 10 with NIR) had a 
positive history for oncologic diseases, most frequently lympho-
ma (35%). The 9% (3/35) of patients had chronic obstructive 
pulmonary disease, the 17% (6/35) had coronary artery disease 
and the 6% (2/35) had a systemic autoimmune disease.
Clinical features of the 28 patients of the control group, who 
experienced a hypersensitivity reaction without any premedica-
tion, were comparable with the patients of the breakthrough 
group regarding distribution of background characteristics in-
cluding age, gender, history of allergic disease, comorbidities, 
NIRs / IRs distribution, and severity of hypersensitivity reac-
tions (table 1). 
ICM used and radiological examinations. Among patients cohort 
with prior breakthrough reactions, most of radiological examina-
tions of hypersensitivity reaction occurred without pharmacolog-
ical premedication, called index reaction, were CT scan (33/38); 
2 were conventional angiography, 2 were cholangiography and 1 
was urography. All the radiological examinations of breakthrough 
reaction of this group were CT scans. Similarly, all radiological 
examinations performed in the control group were CT-scans. 
Among the cohort of patients with prior breakthrough reactions, 
the ICM of the index reaction was known in 18/35 patients 
(51%; table 1 for details). Three out of 35 patients had more 
than one breakthrough reaction, for a total of 38 breakthrough 
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Table 1 - Clinical features of patients studied. 
Breakthrough group Control group
Number of Patients 35 28
Female, n (%) 27 (77%) 21 (75%)
Age, mean (range) 58 (26-78) 60 (28-74)
Immediate / Non-Immediate Reaction 20/15 17/11
Allergic history, n (%) 16 (46%) 14 (50%)
Other drug allergies 12 10








Oncological disease 23 (66%) 17 (61%)
Chronic pulmonary disease 3 (9%) 2 (7%)
Coronary artery diseases 5 (17%) 2 (7%)
Autoimmune disease 2 (6%) 0












ICM of index reaction, n (%) 35 28
Iopromide (non-ionic monomer) 5 (14%) 9 (32%)
Iomeprol (non-ionic monomer) 5 (14%) 11 (39%)
Iodixanol (non-ionic dimer) 4 (11%) 8 (29%)
Iopamidol (non-ionic monomer) 2 (6%) 0
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No difference was observed in clinical/demographic features or 
chronic ACE-inhibitor / beta-blockers / NSAIDs use between 
breakthrough and control groups.
In both groups the rate of chronic use of ACE-inhibitor and/
or beta-blockers and/or NSAIDs was more than 30% (table 
and 6 NIR patients, table 2-3 for details). The STs positive 
ICM matched the culprit ICM in 3 patients of the IR group 
and in 2 patients of the NIR group, respectively. The median 
time interval between the first reaction and skin testing was 4 
months (range 2 - 6). 
Table 2 - Skin testing for patient with IR to ICM.
Pt.
Index reaction Prior breakthrough reaction(s) Last breakthrough reaction
Skin test results1
Severity  ICM Severity ICM Severity ICM 
1 grade III Unknown - - grade II Iopromide -
2 grade III Unknown grade II Unknown grade I Iomeprol IDT 1:100 Iomeprol 
(I, 96) and 1:100 
Iopromide (I, 96)
3 grade III Unknown - - grade II Unknown -
4 grade I Unknown - - grade II Iopromide -
5 grade I Unknown - - grade I Iopromide IDT 1:10 Iopromide 
(I) and 1:1 Iomeprol 
(I, 96)
6 grade III Unknown grade II Iopromide IDT 1:100 
Iopromide (I)
7 grade III Unknown grade I Iomeprol grade I Iomeprol -
8 grade I Unknown - - grade I Unknown -
9 grade I Unknown - - grade I Iopromide -
10 grade I Unknown - - grade I Iopromide IDT 1:100 Iopro-
mide (I)
11 grade I Ioversol - - grade I Iomeprol -
12 grade III Iopromide - - grade II Iodixanol IDT 1:10 Iopromide 
(I), 1:1 Iomeprol (I) 
and 1:1 Iodixanol (I)
13 grade II Iodixanol - - grade II Iopromide -
14 grade III Iopamidol - - grade II Iopromide -
15 grade II Iomeprol - - grade II Iodixanol IDT 1:100 Iomeprol 
(I) and 1:100 
Iopromide (I)
16 grade I Iomeprol - - grade I Iopromide -
17 grade I Iodixanol grade I Iopromide grade I Iopromide -
18 grade II Iopamidol - - grade II Iopromide -
19 grade II Iodixanol - - grade II Iodixanol -
20 grade I Iohexol - - grade II Iodixanol -
1Skin tests included SPTs and IDTs: only positive results are reported. Only 3 patients had two consecutive breakthrough reaction. 
Computed tomography (CT), iodinated contrast media (ICM), Immediate reaction (IR), Intradermal test (IDT), immediate reading (I), 48 hours reading (48), 72 
hours reading (72), 96 hours reading (96).
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Table 3 - Skin testing for patient with NIR to ICM.
Pt. Index reaction Last breakthrough reaction Skin test results1
Severity ICM Severity ICM -
1 Mild Unknown Mild Iomeprol -
2 Mild Unknown Mild Iomeprol -
3 Moderate Unknown Moderate Iopromide IDT 1:10 Iomeprol 
(72) and 1:10 Iopro-
mide (72)
4 Mild Unknown Mild Iopromide -
5 Mild Unknown Moderate Iopromide -
6 Mild Unknown Mild Iodixanol IDT 1:10 Iodixanol 
(96)
7 Mild Iodixanol Mild Iopromide IDT 1:100 Iopromide 
(I) and 1:1 Iodixanol 
(I)
8 Mild Iomeprol Moderate Iopromide -
9 Mild Iopromide Moderate Iomeprol -
10 Moderate Iomeprol Mild Iopromide -
11 Mild Iopromide Mild Iopromide -
12 Mild Iopromide Mild Iopromide -
13 Mild Iomeprol Mild Iomeprol -
14 Mild Unknown Mild Unknown PT iodixanol (48)
15 Mild Iopromide Mild Iopromide -
1Skin tests included SPTs, IDTs and PTs: only positive results are reported. 
Computed tomography (CT), iodinated contrast media (ICM), Non-immediate reaction (NIR), Intradermal test (IDT), Patch test (PT), immediate reading (I), 48 
hours reading (48), 72 hours reading (72), 96 hours reading (96).
Table 4 - Clinical/demographic features and ACE-inhibitor / NSAIDs /Beta blockers chronic use in patients with positive ST’s results. 
Breakthrough group with STs + Control group with STs + P 
Age 57 64 > .05
Female (8/10) 80% (12/16) 75% > .05
Allergy history, n (%) 5/10 (50%) 9/16 (56%) > .05
Other drug allergies 4 7
Common inhalants 1 2
Comorbidities, n (%) 8/10 (80%) 11/16 (69%) > .05
Oncological disease, n (%) 6/10 (60%) 9/16 (56%)
Chronic pulmonary disease, n (%) 1/10 (10%) -
Coronary artery diseases, n (%) 1/10 (10%) 2/16 (13%)
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idemiological and clinical features between the breakthrough 
patients’ cohort and control group. Similarly, the chronic use 
of ACE-inhibitor and/or beta-blockers and/or NSAIDs, which 
may potentially trigger or exacerbate an ICM reaction, was not 
increased in the breakthrough group (table 4). 
However, a deeper reading of the results achieved, evidences 
that most of the so called “breakthrough reactors” with negative 
STs are likely patients with non-allergic breakthrough reactions. 
Overall, 29% of patients are positive at STs for one or more 
ICM, and only 26% of IR and 21% of NIR patients are ST 
positive for the breakthrough reaction’s ICM. This suggest that 
the majority breakthrough reactions are probably non-immuno-
logic reactions, due e.g. to direct histamine release by circulating 
basophils or even steroid-induced flushing. Our clinical experi-
ence supports this view, particularly for the breakthrough IRs. 
On the other hand, only 20% of IR and 13% of NIR patients 
are ST positive for the index reaction’s ICM (from 6 months to 
8 years before STs), paralleling the data already published by 
ENDA group for patients tested after 6 months from the hyper-
sensitivity reac tion, in which ST positive rate was around 18% 
for IR and 22% for NIR respectively (10).
On the other hand, breakthrough reactors with positive STs 
might be patients who experienced hypersensitivity reactions to 
the same ICM of index reaction despite premedication (in those 
cases in which ICM was unknown), or patients with multiple 
ICMs allergy due to cross-reactive compounds. 
All these considerations reflect the heterogeneity of the break-
through reactors’ condition; suggesting that a considerable 
number of breakthrough reactors are probably patients who 
experience non-allergic hypersensitivity reactions or patients in 
which breakthrough reactions could be mostly prevented by a 
proper skin testing after index reaction. Our analysis is limited 
by the role of the in vivo tests in breakthrough reactions, thus 
not including the in vitro diagnostics (as basophil activation 
test) or triptase levels, which may have contributed to explain 
the results we achieved, especially for those patients who expe-
rienced an IR. Similarly, it would be useful to know if patients 
with a supposed non-clearly immune-mediated rash had a prior 
history of cutaneous manifestation as atopic dermatitis, pressure 
urticaria or dermagraphism, but these data are missing because 
of the retrospective nature of our analysis. 
Unlike from patients with IR, the lower ST positive rate in 
breakthrough reactors with NIR is not easy to explain and we 
can’t offer a possible explanation of the responsible mechanism. 
Unfortunately, we didn’t use the drug provocative test (DTP) 
with an alternative ICM, which could help in identification of 
a safe, alternative compound, especially for patients with NIR 
(17-20), increasing the diagnostic yield. The usefulness of DTP 
in contrast media hypersensitivity is a recent acquisition and the 
procedure needs to be standardized (19). 
4). Among the patients who had prior breakthrough reactions 
with positive STs (10 patients), 40% chronically used medica-
tions potentially exacerbating a ICM hypersensitivity reaction 
(ACE-inhibitor 2 patients, NSAIDs 1 patient, beta blockers 1 
patient). In the control group, 38% (n = 16) of patients with 
positive STs chronically used these medications (ACE-inhib-
itor 2 patients, NSAIDs 3 patients, beta blockers 1 patients). 
There was no statistical difference between the breakthrough 
and the control group of patients. Results are summarized in 
table 4.
Furthermore, there was any significant difference in allergy his-
tory, age, sex and other demographic features in STs-positive 
subsets of both groups (table 4).
Discussion
The problem of repeated hypersensitivity reactions to ICM de-
spite premedications, formerly called breakthrough reactions, 
represent a major issue in clinical setting if a new contrast-en-
hanced radiological examination is required. From a clinical 
perspective, the diagnosis by STs of the ICM culprit (if not 
known) or other cross-reactive ICMs is the prerequisite for se-
lection of an alternative compound and prevention of a possible 
new reaction (7-10). Overall, the use of STs has not yet been 
assessed in patients with prior breakthrough reactions (occurred 
despite premedication), whereas a growing body of literature re-
ported the sensitivity of these testing around 50% for patients 
who experienced ICM hypersensitivity reaction (10-14).
In the present study we aimed to retrospectively evaluate the 
rate of positive skin test (STs) in 35 patients with previous ICM 
breakthrough reactions, and to compare this results to a control 
group of patients who experienced an ICM hypersensitivity re-
action occurred without premedication. 
We included only those patients in which STs were performed 
within 6 months from the last breakthrough reaction, in or-
der to optimize the rate of positive testing. Interestingly, we 
found that the STs were positive in 29% (10/35) of patient’s 
cohort with prior breakthrough reactions, equally distributed 
between IR group and NIR groups, versus 57% (16/28) of the 
non-breakthrough control group (p < 0.05, table 2 and 3). Of 
note, the STs rate of the control group was consistent to those 
already published (10). 
Overall, less than one third of patients with prior breakthrough 
reactions has immunologically proven ICM reactions (with 
positive STs). A possible explanation to this unexpected result 
may likely have been the unintentional selection of the pop-
ulation studied. In fact, patients with repeated reactions de-
spite premedication are usually patients who undergo to sev-
eral contrast-enhanced radiological examination because of an 
oncologic or cardiovascular disease, unlike the ENDA patients’ 
cohort. Nevertheless, no significant difference was found in ep-
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hypersensitivity reactions to iodinated contrast media. Curr Opin 
Allergy Clin Immunol. 2013;13(4):345-53.
20. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J 
et al. Drug provocation testing in the diagnosis of drug hypersen-
sitivity reactions: general considerations. Allergy. 2003;58:854-63.
Other limitations consist of as the sample size of the patients’ 
cohort or the number of ICM tested. We performed the STs 
with iomeprol, iopromide, and iodixanol in all patients, since 
only these 3 ICM were used in our Institute in the last 8 years. 
A fourth ICM (iopamidol, 2 patients) was added for STs only 
for those patients who experienced the index reaction in other 
hospitals, with a known ICM different from the previous three. 
Although ENDA study group used at least four ICM for STs 
(10), our control group showed a rate of positive STs performed 
between 2 and 6 months comparable to that of ENDA study. 
Finally, we performed STs using also 1:1 ICM dilution, which 
is not recommended by ENDA because of the risk of false posi-
tives (10), albeit several authors already used it with different re-
sults (11-14). Since in our experience 1:1 dilution of ICM may 
be useful if carefully read by the experienced allergist, we per-
formed it in our cohort of patients. Furthermore, the STs rate 
of patients with prior breakthrough reaction was lower than the 
control group albeit 1:1 ICM dilutions, and STs rate of control 
group was not substantially higher compared to those reported 
by ENDA (10).
Despite these limitations and the heterogeneity of our cohort, 
we first observed that patients with prior breakthrough reactions 
have lower immunologically proven ICM reactions (with posi-
tive STs) compared to non-breakthrough reactions. Our results 
reappraise the role of breakthrough reactions; some of those are 
probably non-allergic hypersensitivity reactions or true allergic 
reactions that could be prevented by a proper, well-timed diag-
nostic skin testing. Larger prospective studies are needed to con-
firm these results, with a more careful analysis of patients’ risk 
factors, a laboratory assessment that includes an in vitro allergy 
diagnostics, as for example tryptase levels during acute reaction 
for patients with IR, and hopefully DTP with an alternative 
ICM for selected cases, especially those with ST negative NIR. 
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